The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of metronomic oral topotecan in combination with pazopanib utilizing a daily dosing schedule to treat recurrent or persistent gynecologic tumors.
Todd D. Tillmanns
Research Funding - GlaxoSmithKline
Mark E. Reed
No relevant relationships to disclose
Melissa C. Privett
No relevant relationships to disclose
Amanda L. Johns
No relevant relationships to disclose
Mark S. Walker
No relevant relationships to disclose
Arthur C. Houts
No relevant relationships to disclose